Ardelyx, Inc. (ARDX)

NASDAQ: ARDX · Delayed Price · USD
0.932
0.008 (0.82%)
At close: Jan 14, 2022 4:00 PM
0.920
-0.012 (-1.298%)
After-hours:Jan 14, 2022 6:49 PM EST

Company Description

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally.

The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.

It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis.

The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.

Ardelyx, Inc.
Ardelyx Logo
CountryUnited States
Founded2007
IPO DateJun 19, 2014
IndustryBiotechnology
SectorHealth Care
Employees129
CEOMichael Raab

Contact Details

Address:
34175 Ardenwood Blvd
Fremont, California 94555-3653
United States
Phone510 745 1700
Websiteardelyx.com

Stock Details

Ticker SymbolARDX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001437402

Key Executives

NamePosition
Michael G. RaabPresident, Chief Executive Officer and Director
Justin A. Renz CPA, MST, M.S.T., MBAChief Financial Officer and Chief Accounting Officer
Susan RodriguezChief Commercial Officer
Elizabeth A. GrammerChief Legal and Administrative Officer and Secretary
Kimia KeshtbodManager of Corporate Communications and Investor Relations
David P. RosenbaumChief Development Officer
Robert C. BlanksChief Regulatory Affairs and Quality Assurance Officer
Karen HarriganSenior Director Market Development
Dan PavicichSenior Director of Market Development
Dr. Laura A. Williams M.D., M.P.H.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jan 12, 20224Statement of changes in beneficial ownership of securities
Jan 12, 20224Statement of changes in beneficial ownership of securities
Jan 12, 20224Statement of changes in beneficial ownership of securities
Jan 12, 20224Statement of changes in beneficial ownership of securities
Jan 12, 20224Statement of changes in beneficial ownership of securities
Jan 12, 20224Statement of changes in beneficial ownership of securities
Jan 10, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Dec 29, 2021SC 13D/AGeneral statement of acquisition of beneficial ownership
Dec 27, 20214Statement of changes in beneficial ownership of securities
Dec 27, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings